BioSpace News Archive

Santhera Pharmaceuticals announces a strategic change to its management team with the appointment of Dario Eklund as CEO, effective December 1, 2019.

Shanghai Green Valley Pharmaceuticals announced that China’s National Medical Products Administration has approved Oligomannate as new drug for the treatment of mild to moderate Alzheimer’s disease.

Leveraging the concept of virtual assistants, BASF expertise becomes available to its customers, supporting during all stages of the drug development process

ECGmd is now recognized as a medical device in Europe, capable of providing medical-grade ECG output from Shimmer’s wearable sensor

A*STAR’s Institute of Bioengineering and Nanotechnology has teamed up with the Singapore Institute of Advanced Medicine Holdings Pte Ltd to explore how to better tackle nasopharyngeal carcinoma, a type of head and neck cancer, through targeted proton therapy.

Bench to bedside research provides a new business opportunity: Newly discovered antibodies against iRhom2 block several pro-inflammatory pathways simultaneously, promising significant improvement over current autoimmune therapies.

First hospital in US to acquire French medtech firm’s CT-Navigation™ system to increase accuracy in radiology procedures, while decreasing treatment times and radiation exposure of patients and healthcare professionals

Eveliqure Biotechnologies announces the grant of a Wellcome Trust Innovator Award that supports the early clinical development of its Shigella-ETEC combination vaccine with ~£500K and complements the previously secured ~€11 million funding from public sources for the vaccine’s development

One of the things the company reported that has raised eyebrows is that the drug statistically improved cognitive function in the patients as early as week 4. This would be a very quick patient response—and for that matter, given that many Alzheimer’s studies run for years, a 36-week study is at least half the length of a typical Alzheimer’s trial.

They announced an exclusive license deal and research agreement to develop cord-blood derived chimeric antigen receptor-directed natural killer (CAR NK)-cell therapies.